Turkish officials are psyched up for a big leap in its pharmaceutical business. According to a Pricewaterhouse Coopers report commissioned by the Turkish pharma industry, drug sales are poised to grow to $23.3 billion by 2023, up from $5 billion last year--provided the government makes some key moves.
Turkey's pharma market isn't as high-profile as the oft-celebrated China or India. But that doesn't mean foreign drugmakers aren't looking for ways to beef up their operations in the country.
Given the measly growth projections for U.S. and Europe, it's no surprise that expansion-minded drugmakers are looking eastward.
Need more proof that Turkey is pharma's latest promised land? Three Big Pharmas are said to be circling the Turkish drugmaker MN Pharmaceuticals. GlaxoSmithKline ( $GSK ), Eli Lilly ( $LLY ) and Pfizer (
Raise your hand if you think the hottest emerging market for M&A is either India, China or Brazil. Well, if you raised your hand, you're wrong. A Bloomberg analysis found dealmaking in Turkey has
Emerging markets continue to beckon Big Pharma. Eli Lilly ( $LLY ) is in partnership talks with Turkey's Mustafa Nevzat Ilac--MN Pharmaceuticals--a generics maker that also turns out active
Turkish drugmaker Bilim Ilac may have found a private-equity investor. Reuters reports the pharma company is in talks to sell a stake to Actera, a Turkish-focused firm with a $500 million-plus fund
GlaxoSmithKline is one of three remaining bidders for the Turkish generics firm Biofarma. Bloomberg reports that GSK is competing with two other multinational companies, with a winning bidder to be
Takeda Pharmaceutical ( TKPH ) is taking on the world. It's launching four new overseas subsidiaries to market its products, aiming to expand its territory substantially. The four units will be based
More emerging markets excitement: Sources tell Reuters that Pfizer is kicking tires at Turkey's largest drug company, Abdi Ibrahim. That fits with an executive pledge last month to line up